Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol for sedation in mechanically ventilated ICU patients
ChiCTR2200058409Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of remimazolam in Requirement for mechanical ventilation (MV) and critical illness (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Light sedation at 0 and 24 hours. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Requirement for mechanical ventilation (MV)critical illness
Beyond the preview
Go deeper on ChiCTR2200058409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058409.